Journal article · 2014 · Open access
Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics, 13(5), 1356–1368 · Published 1 May 2014 · DOI 10.1158/1535-7163.mct-13-1021
In brief
“Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer” is a 2014 journal article by Toni Michel Brand and 10 co-authors, published in Molecular Cancer Therapeutics. OpenAlex counts 67 citations as of 21 November 2026. It is open access: the full text is free to read at PubMed Central.
- Citations
- 67
- Most cited in
- 2018 (8)
- Field-weighted impact
- 3.88
- References
- 45
- Authors
- 11
Abstract
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high percentage of TNBCs overexpresses the EGF receptor (EGFR), yet EGFR inhibition has yielded little clinical benefit. Over the last decade, advances in EGFR biology have established that EGFR functions in two distinct signaling pathways: (i) classical membrane-bound signaling and (ii) nuclear signaling. Previous studies have demonstrated that nuclear EGFR (nEGFR) can enhance resistance to anti-EGFR therapies and is correlated with poor overall survival in breast cancer. On the basis of these findings, we hypothesized that nEGFR may promote intrinsic resistance to cetuximab in TNBC. To examine this question, a battery of TNBC cell lines and human tumors were screened and found to express nEGFR. Knockdown of EGFR expression demonstrated that TNBC cell lines retained dependency on EGFR for proliferation, yet all cell lines were resistant to cetuximab. Furthermore, Src Family Kinases (SFKs) influenced nEGFR translocation in TNBC cell lines and in vivo tumor models, where inhibition of SFK activity led to potent reductions in nEGFR expression. Inhibition of nEGFR translocation led to a subsequent accumulation of EGFR on the plasma membrane, which greatly enhanced sensitivity of TNBC cells to cetuximab. Collectively, these data suggest that targeting both the nEGFR signaling pathway, through the inhibition of its nuclear transport, and the classical EGFR signaling pathway with cetuximab may be a viable approach for the treatment of patients with TNBC.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Brand, T. M., Iida, M., Dunn, E., Luthar, N., Kostopoulos, K. T., Corrigan, K. L., Wleklinski, M. J., Yang, D. T., Wisinski, K. B., Salgia, R., & Wheeler, D. L. (2014). Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 13(5), 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021
MLA 9
Brand, Toni Michel, et al. “Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics, vol. 13, no. 5, 2014, pp. 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021.
Chicago
Brand, Toni Michel, Mari Iida, Emily Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, et al. 2014. “Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics 13 (5): 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021.
Harvard
Brand, T. M. et al. (2014) ‘Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer’, Molecular Cancer Therapeutics, 13(5), pp. 1356–1368. doi:10.1158/1535-7163.mct-13-1021.
IEEE
T. M. Brand et al., “Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer,” Molecular Cancer Therapeutics, vol. 13, no. 5, pp. 1356–1368, 2014, doi: 10.1158/1535-7163.mct-13-1021.
BibTeX
@article{brand2014nuclear,
title = {{Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer}},
author = {Brand, Toni Michel and Iida, Mari and Dunn, Emily and Luthar, Neha and Kostopoulos, Kellie T. and Corrigan, Kelsey L. and Wleklinski, Matthew J. and Yang, David T. and Wisinski, Kari Braun and Salgia, Ravi and Wheeler, Deric L.},
journal = {Molecular Cancer Therapeutics},
year = {2014},
volume = {13},
number = {5},
pages = {1356--1368},
doi = {10.1158/1535-7163.mct-13-1021},
url = {https://doi.org/10.1158/1535-7163.mct-13-1021}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 7 | |
| 2018 | 8 | |
| 2019 | 6 | |
| 2020 | 6 | |
| 2021 | 6 | |
| 2022 | 2 | |
| 2023 | 6 | |
| 2024 | 5 | |
| 2025 | 1 | |
| 2026 | 1 |
Its field-weighted citation impact is 3.88: it has been cited 3.88 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- triple-negative breast cancer
- nuclear EGFR
- EGFR signaling
- cetuximab resistance
- Src family kinases
- nuclear translocation
- EGFR knockdown
- anti-EGFR therapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Brand, T. M., Iida, M., Dunn, E., Luthar, N., Kostopoulos, K. T., Corrigan, K. L., Wleklinski, M. J., Yang, D. T., Wisinski, K. B., Salgia, R., & Wheeler, D. L. (2014). Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 13(5), 1356–1368. https://doi.org/10.1158/1535-7163.mct-13-1021
How many times has this paper been cited?
67 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Toni Michel Brand, Mari Iida, Emily Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David T. Yang, Kari Braun Wisinski, Ravi Salgia, Deric L. Wheeler.
What is the DOI of this paper?
10.1158/1535-7163.mct-13-1021, permanently at https://doi.org/10.1158/1535-7163.mct-13-1021. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.